Recce Pharmaceuticals Secures $8M Placement and Launches $3M Entitlement Offer to Shareholders
Retrieved on:
Wednesday, September 13, 2023
“We are thrilled to receive such strong financial interest, particularly among global investment funds,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
Key Points:
- “We are thrilled to receive such strong financial interest, particularly among global investment funds,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
- Each of the Directors of the Company intends to subscribe for their respective entitlement partially or in full under the entitlement offer.
- Any new shares not applied for under the entitlement offer and any entitlements that would have been offered to ineligible shareholders if they had been entitled to participate in the offer will form part of the shortfall from the entitlement offer.
- Further information in relation to the entitlement offer will be sent to eligible shareholders in the offer booklet and accompanying personalized entitlement and acceptance form, which are expected to be dispatched on Friday, September 15, 2023.